The Board of GlaxoSmithKline Consumer Nigeria Plc (GSK) has announced that the company whose market capitalization is worth N20.1bn has received the nod of the Securities and Exchange Commission of its scheme of arrangement which will result in delisting from the Nigerian Exchange Limited (NGX).
The approval follows the Court Ordered Meeting held on December 5, 2023 – at which the shareholders of GlaxoSmithKline Consumer Nigeria Plc approved the proposed Scheme of Arrangement.
This was contained in the company’s Notice to the NGX and investing Public on Thursday, January 18, 2024.
